Sign in →

TEST ID PLA2I Phospholipase A2 Receptor, Immunofluorescence, Serum

Reporting Name

PLA2R, Immunofluorescence, S

Specimen Type

Serum


Ordering Guidance


This test can be used in a complementary fashion with a quantitative enzyme-linked immunosorbent assay to confirm a positive result, especially if it is a low-level titer. Since the immunofluorescence is more sensitive, it can also be used to detect or follow patients with low level antibodies not detected by ELISA.  



Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL 

Collection Instructions: Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  14 days
  Ambient  8 hours

Method Name

Indirect Immunofluorescence Assay (IFA)

Reject Due To

Gross hemolysis Reject
Gross lipemia OK

Reference Values

Negative

Day(s) Performed

Monday, Wednesday, Friday

Report Available

3 to 7 days

Specimen Retention Time

7 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

86255

Forms

If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.

Useful For

Distinguishing primary from secondary membranous nephropathy in patients with low levels of anti-phospholipase A2 receptor (PLA2R) antibodies

 

Screening for anti-PLA2R antibodies

 

Monitoring patients with membranous nephropathy at very low antibody titers

Highlights

Anti-phospholipase A2 receptor (PLA2R) antibodies are highly specific for the diagnosis of primary membranous nephropathy.

 

As many as 70% to 75% of patients with primary membranous nephropathy are positive for anti-PLA2R.

 

This test can be used to identify whether a specific autoantibody is present in a patient with biopsy proven membranous nephropathy, or in a patient without a renal biopsy but with a clinical picture consistent with membranous nephropathy.